**Suppl 3.** Concordance between *ERBB2* CNA evaluated by targeted next-generation sequencing and HER2 IHC (4B5)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | | **Number of patients** | | |
| **HER2 IHC (4B5)** | | **Total** |
| **Score 3+/ 2+** | **Score 1+/0** |
| *ERBB2* CNA evaluated by targeted next-generation sequencing | > 1.70-fold change | 9 | 0 | 9 |
| ≤ 1.70-fold change | 2 | 30 | 32 |
| Total | 11 | 30 | 41 |
|  | Positive percent agreement | 81.8% | | |
| Negative percent agreement | 100.0% | | |
| Overall percent agreement | 95.1% | | |
| Cohen’s kappa (95% CI) | 0.87 (0.69–1.05) | | |

*ERBB2*, erb-b2 receptor tyrosine kinase 2; CNA, copy number alteration; HER2, human epidermal growth factor receptor 2; IHC; immunohistochemistry.